Current Approaches to Arterial Hypertension Management in Children and Adolescents: Clinical Guidelines Review
Larisa A. Balykova, 
Irina V. Leontyeva,
Anna V. Krasnopolskaya,
Dinara I. Sadykova,
Lilia S. Mashkina,
Irina Yu. Chegodaeva,
Zulfiia R. Khabibrakhmanova,
Evgenia S. Slastnikova,
Lilia F. Galimova,
Svetlana A. Ushakova
Irina V. Leontyeva,
Anna V. Krasnopolskaya,
Dinara I. Sadykova,
Lilia S. Mashkina,
Irina Yu. Chegodaeva,
Zulfiia R. Khabibrakhmanova,
Evgenia S. Slastnikova,
Lilia F. Galimova,
Svetlana A. Ushakova https://doi.org/10.15690/vsp.v20i4.2281
Abstract
The prevalence of arterial hypertension (AH) in children and adolescents is increasing, thus it is crucial and topical to make pediatricians familiar with modern approaches in drug and drug-free therapy for AH. The aim of this review was to provide the overview of international and Russian guidelines for the AH treatment. We have searched the following keywords in PubMed: guidelines, arterial hypertension treatment, guidelines of management, pediatric hypertension. Reviews, clinical guidelines, and original articles published from 2010 to 2020 were analyzed. Detailed description of AH management in children and adolescents is presented. Approaches to drug-free correction of increased blood pressure (BP) are discussed in detail, indications for antihypertensive therapy are described, characteristics of the main classes of antihypertensive drugs are given (indications, contraindications, and possible side effects). Principles of refractory AH management and antihypertensive drugs combinations are also described.
Keywords
Supporting agencies: Not specified
About the Authors
Larisa A. Balykova
Ogarev Mordovia State University
Russian Federation
Disclosure of interest:
Russian Federation
Saransk
Disclosure of interest:
Not declared
Irina V. Leontyeva
Veltischev Research and Clinical Institute for Pediatrics
Russian Federation
Disclosure of interest:
Russian Federation
Moscow
Disclosure of interest:
Not declared
Anna V. Krasnopolskaya
Ogarev Mordovia State University
Russian Federation
Disclosure of interest:
Russian Federation
Saransk
Disclosure of interest:
Not declared
Dinara I. Sadykova
Kazan State Medical University
Russian Federation
Disclosure of interest:
Russian Federation
Kazan
Disclosure of interest:
Not declared
Lilia S. Mashkina
Ogarev Mordovia State University
Russian Federation
Disclosure of interest:
Russian Federation
Saransk
Disclosure of interest:
Not declared
Irina Yu. Chegodaeva
Ogarev Mordovia State University
Russian Federation
Disclosure of interest:
Russian Federation
Saransk
Disclosure of interest:
Not declared
Zulfiia R. Khabibrakhmanova
Kazan State Medical University
Russian Federation
Disclosure of interest:
Russian Federation
Kazan
Disclosure of interest:
Not declared
Evgenia S. Slastnikova
Republican Children's Clinical Hospital
Russian Federation
Disclosure of interest:
Russian Federation
Kazan
Disclosure of interest:
Not declared
Lilia F. Galimova
Kazan State Medical University
Russian Federation
Disclosure of interest:
Russian Federation
Kazan
Disclosure of interest:
Not declared
Svetlana A. Ushakova
City Polyclinic No. 4
Russian Federation
Disclosure of interest:
Russian Federation
Tyumen
Disclosure of interest:
Not declared
References
1. Aleksandrov AA, Kislyak OA, Leont'eva IV, Rozanov VB. Diagnostika, lechenie i profilaktika arterial'noi gipertenzii u detei i podrostkov: Russian recommendations (second revision). Cardiovascular Therapy and Prevention. 2009;8(4 S1):1-32. (In Russ).
2. Song P, Zhang Y Yu J, et al. Global prevalence of hypertension in children: a systematic review and meta-analysis. JAMA Pediatr. 2019;173(12):1154-1163. 10.1001/jamapediatrics.2019.3310
3. Rosner B, Cook NR, Daniels S, Falkner B. Childhood blood pressure trends and risk factors for high blood pressure: the NHANES experience 1988-2008. Hypertension. 2013;62(2):247-254. doi: 10.1161/HYPERTENSI0NAHA.111.00831
4. Chung ST, Onuzuruike AU, Magge SN. Cardiometabolic risk in obese children. Ann NY Acad Sci. 2018;1411(1):166-183. doi: 10.1111/nyas.13602
5. Kelishadi R, Mirmoghtadaee P, Najafi H, Keikha M. Systematic review on the association of abdominal obesity in children and adolescents with risk factors. J Res Med Sci. 2015;20(3):294-307.
6. Xi B, Zhang T, Li S, et al. Can Pediatric Hypertension Criteria Be Simplified? APrediction Analysis ofSubclinical Cardiovascular Outcomes from the Bogalusa Heart Study. Hypertension. 2017;69(4):691-696. doi: 10.1161/HYPERTENSI0NAHA.116.08782
7. Flynn JT, Kaelber DC, Baker-Smith CM, et al. Clinical Practice Guideline for Screening and Management of High Blood Pressure in Children and Adolescents. Pediatrics. 2017;140(3):e20171904. doi: 10.1542/peds.2017-1904
8. Lurbe E, Agabiti-Rosei E, Cruickshank JK, et al. 2016 European Society of Hypertension guidelines for the management of high blood pressure in children and adolescents. J Hypertens. 2016;34(10):1887-1920. doi: 10.1097/HJH.0000000000001039
9. Dionne JM, Harris KC, Benoit G, et al. Hypertension Canada Guideline Committee. Hypertension Canada's 2017 Guidelines for the Diagnosis, Assessment, Prevention, and Treatment of Pediatric Hypertension. Can J Cardiol. 2017;33(5):577-585. doi: 10.1016/j.cjca.2017.03.007
10. Aleksandrov AA, Kisliak OA, Leontyeva IV. Clinical guidelines on arterial hypertension diagnosis, treatment and prevention in children and adolescents. Systemic Hypertension. 2020;17(2):7-35. (In Russ). doi: 10.26442/2075082X.2020.2.200126
11. Khoury M, Urbina EM. Hypertension in adolescents: diagnosis, treatment, and implications. Lancet Child Adolesc Health. 2021;5(5):357-366. doi: 10.1016/S2352-4642(20)30344-8
12. Blanchette E, Flynn JT. Implications of the 2017 AAP Clinical H Practice Guidelines for Management of Hypertension in Children and Adolescents: a Review. Curr Hypertens Rep. 2017;21(5):35. doi: 10.1007/s11906-019-0943-x
13. Matossian D. Pediatric Hypertension. Pediatr Ann. 2018;47(12):e499-e503. doi: 10.3928/19382359-20181119-01
14. Salas P, Gonzalez C, Carrillo D, et al. Blood hypertension in children. Guideliness for diagnosis and treatment. Part 2 Pediatric Nephrology Branch, Chilean Pediatric Society. Rev Chil Pediatr. 2019;90(3):336-342. doi: 10.32641/rchped.v90i3.1007
15. Goel M, Pal P Agrawal A, Ashok C. Relationship of body mass index and other life style factors with hypertension in adolescents. Ann Pediatr Cardiol. 2016;9(1):29-34. doi: 10.4103/0974-2069.171393
16. Hvidt KN, Olsen MH, Ibsen H, Holm JC. Effect of changes in BMI and waist circumference on ambulatory blood pressure in obese children and adolescents. J Hypertens. 2014;32(7):1470-1477. doi: 10.1097/HJH.0000000000000188
17. Bondyra-Wisniewska B, Myszkowska-Ryciak J, Harton A. Impact of Lifestyle Intervention Programs for Children and Adolescents with Overweight or Obesity on Body Weight and Selected Cardiometabolic Factors-A Systematic Review. Int J Environ Res Public Health. 2021;18(4):2061. doi: 10.3390/ijerph18042061
18. Zhang T, Zhang H, Li S, et al. Impact of adiposity on incident hypertension is modified by insulin resistance in adults: longitudinal observation from the Bogalusa Heart Study. Hypertension. 2016;67(1):56-62. doi: 10.1161/HYPERTENSIONAHA.115.06509
19. Barnes TL, Crandell JL, Bell RA, et al. Change in DASH diet score and cardiovascular risk factors in youth with type 1 and type 2 diabetes mellitus: The SEARCH for Diabetes in Youth Study. Nutr Diabetes. 2013;3(10):e91. doi: 10.1038/nutd.2013.32
20. Juonala M, Viikari JS, Kahonen M, et al. Life-time risk factors and progression of carotid atherosclerosis in young adults: the Cardiovascular Risk in Young Finns study. Eur Heart J. 2010;31(14):1745-1751. doi: 10.1093/eurheartj/ehq141
21. Yuan WL, Kakinami L, Gray-Donald K, et al. Influence of dairy product consumption on children's blood pressure: results from the QUALITY cohort. J Acad Nutr Diet. 2013;113(7):936-941. doi: 10.1016/j.jand.2013.03.010
22. Buendia JR, Bradlee ML, Daniels SR, et al. Longitudinal effects of dietary sodium and potassium on blood pressure in adolescent girls. JAMA Pediatr. 2015;169(6):560-568. doi: 10.1001/jamapediatrics.2015.0411
23. Saneei P, Hashemipour M, Kelishadi R, et al. Effects of recommendations to follow the Dietary Approaches to Stop Hypertension (DASH) diet vs. usual dietary advice on childhood metabolic syndrome: a randomised cross-over clinical trial. Br J Nutr. 2013;110(12):2250-2259. doi: 10.1017/S0007114513001724
24. Niinikoski H, Jula A, Viikari J, et al. Blood pressure is lower in children and adolescents with a lowsaturated-fat diet since infancy: the special Turku coronary risk factor intervention project. Hypertension. 2009;53(6):918-924. doi: 10.1161/HYPERTENSI0NAHA.109.130146
25. Davis JN, Ventura EE, Cook LT, et al. LA Sprouts: a gardening, nutrition, and cooking intervention for Latino youth improves diet and reduces obesity. J Am Diet Assoc. 2011;111(8):1224-1230. doi: 10.1016/j.jada.2011.05.009
26. Yang Q, Zhang Z, Kuklina EV, et al. Sodium intake and blood pressure among US children and adolescents. Pediatrics. 2012;130(4):611-619. doi: 10.1542/peds.2011-3870
27. Boegehold MA. The effect of high salt intake on endothelial function:reduced vascular nitric oxide in the absence of hypertension. J Vasc Res. 2013;50(6):458-467. doi: 10.1159/000355270
28. Machado IBS, Tofanelli MR, Saldanha da Silva AA, Simoes E Silva AC. Factors Associated with Primary Hypertension in Pediatric Patients: An Up-to-Date. Curr Pediatr Rev. 2021;17(1):15-37. doi: 10.2174/1573396317999210111200222.
29. Farpour-Lambert NJ, Aggoun Y, Marchand LM, et al. Physical activity reduces systemic blood pressure and improves early markers of atherosclerosis in prepubertal obese children. J Am Coll Cardiol. 2009;54(25):2396-2406. doi: 10.1016/j.jacc.2009.08.030
30. Garcia-Hermoso A, Saavedra JM, Escalante Y. Effects of exercise on resting blood pressure in obese children: a meta-analysis of randomized controlled trials. Obes Rev. 2013;14(11):919-928. doi: 10.1111/obr.12054
31. Fridolfsson J, Buck C, Hunsberger M, et al. Family consortium. High-intensity activity is more strongly associated with metabolic health in children compared to sedentary time: a cross-sectional study of the I.Family cohort. IntJ BehavNutrPhys Act. 2021;18(1):90. doi: 10.1186/s12966-021-01156-1
32. WHO. Physical activity. 26 November 2020. World Health Organization. Available online: https://www.who.int/news-room/fact-sheets/detail/physical-activity. Accessed on October 6, 2021.
33. Black HR, Sica D, Ferdinand K, et al. Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 6: Hypertension: A Scientific Statement from the American Heart Association and the American College of Cardiology. Circulation. 2015;132(22):e298-e302. doi: 10.1161/CIR.0000000000000242
34. Baker-Smith CM, Pietris N, Jinadu L. Recommendations for exercise and screening for safe athletic participation in hypertensive youth. Pediatr Nephrol. 2020;35(5):743-752. doi: 10.1007/s00467-019-04258-y
35. Cai L, Wu Y, Wilson RF, et al. Effect of childhood obesity prevention programs on blood pressure: a systematic review and meta-analysis. Circulation. 2014;129(18):1832-1839. doi: 10.1161/CIRCULATIONAHA.113.005666
36. Zhu L, Liu J, Yu Y, Tian Z. Effect of high-intensity interval training on cardiometabolic risk factors in childhood obesity: a meta-analysis. J Sports Med Phys Fitness. 2021;61(5):743-752. doi: 10.23736/S0022-4707.20.11329-X
37. Gregoski MJ, Barnes VA, Tingen MS, et al. Breathing awareness meditation and Life Skills Training programs influence upon ambulatory blood pressure and sodium excretion among African American adolescents. J Adolesc Health. 2011;48(1):59-64. doi: 10.1016/j.jadohealth.2010.05.019
38. Barnes VA, Kapuku GK, Treiber FA. Impact of transcendental meditation on left ventricular mass in African American adolescents. Evid Based Complement Alternat Med. 2012;2012:923153. doi: 10.1155/2012/923153
39. Sieverdes JC, Mueller M, Gregoski MJ, et al. Effects of Hatha yoga on blood pressure, salivary а-amylase, and cortisol function among normotensive and prehypertensive youth. J Altern Complement Med. 2014;20(4):241-250. doi: 10.1089/acm.2013.0139
40. Luehrs RE, Zhang D, Pierce GL, et al. Cigarette Smoking and Longitudinal Associations With Blood Pressure: The CARDIA Study. J Am Heart Assoc. 2021;10(9):e019566. doi: 10.1161/JAHA.120.019566
41. Chazova IE, Zhernakova YuV. Clinical guidelines. Diagnosis and treatment of arterial hypertension. Systemic Hypertension. 2019;16(1):6-31. (In Russ). doi: 10.26442/2075082X.2019.1.190179
42. Nowak D, Jasionowski A. Analysis of the Consumption of Caffeinated Energy Drinks among Polish Adolescents. Int J Environ Res Public Health. 2015;12(7):7910-7921. doi: 10.3390/ijerph120707910
43. Kaelber DC, Liu W, Ross M, et al. Diagnosis and Medication Treatment of Pediatric Hypertension: A Retrospective Cohort Study. Pediatrics. 2016;138(6):e20162195. doi: 10.1542/peds.2016-2195
44. Tirosh A, Afek A, Rudich A, et al. Progression of normotensive adolescents to hypertensive adults: a study of 26,980 teenagers. Hypertension. 2010;56(2):203-209. doi: 10.1161/HYPERTENSIONAHA.109.146415
45. Sladowska-Kozfowska J, Litwin M, Niemirska A, et al. Change in left ventricular geometry during antihypertensive treatment in children with primary hypertension. Pediatr Nephrol. 2011;26(12):2201-2209. doi: 10.1007/s00467-011-1916-8
46. Wuhl E, Trivelli A, Picca S, et al. for the ESCAPE Trial Group. Strict blood-pressure control and progression of renal failure in children. N Engl J Med. 2009;361(17):1639-1650. doi: 10.1056/NEJMoa0902066
47. Seeman T, Dusek J, Vondrak K, et al. Ramipril in the treatment of hypertension and proteinuria in children with chronic kidney diseases. Am J Hypertens. 2004;17(5 Pt 1):415-420. doi: 10.1016/j.amjhyper.2004.01.008
48. Chaturvedi S, Lipszyc DH, Licht C, et al. Pharmacological interventions for hypertension in children. Evid Based Child Health. 2014;9(3):498-580. doi: 10.1002/14651858.CD008117.pub2
49. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension: 4. Effects of various classes of antihypertensive drugs-overview and meta-analyses. J Hypertens. 2015;33:195-211. doi: 10.1097/HJH.0000000000000447
50. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension: 5. Head-to-head comparisons of various classes of anti hypertensive drugs — overview and meta-analyses. J Hypertens. 2015;33(7):1321-1341. doi: 10.1097/HJH.0000000000000614
51. Gilbert N, Hage A. Treatment of arterial hypertension in children and adolescents. Update of therapeutic options. Med Monatsschr Pharm. 2015;38(4):120-131. quiz 133-134.
52. Ferguson MA, Flynn JT. Rational use of anthypertensive medications in children. Pediatr Nephrol. 2013;29(6):979-988. doi: 10.1007/s00467-013-2510-z
53. Maahs DM, Daniels SR, de Ferranti SD, et al. Cardiovascular disease risk factors in youth with diabetes mellitus: a scientific statement from the American Heart Association. Circulation. 2014;130:1532-1558. doi: 10.1161/CIR.0000000000000094
54. Kupferman JC, Aronson Friedman L, Cox C, et al. BP control and left ventricular hypertrophy regression in children with CKD. J Am Soc Nephrol. 2014;25(1):167-174. doi: 10.1681/ASN.2012121197
55. Niebauer J, Borjesson M, Carre F, et al. Recommendations for participation in competitive sports of athletes with arterial hypertension: a position statement from the sports cardiology section of the European Association of Preventive Cardiology (EAPC). Eur Heart J. 2018;39(40):3664-3671. doi: 10.1093/eurheartj/ehy511
56. Lu YT, Fan P, Zhang D, et al. Overview of Monogenic Forms of Hypertension Combined With Hypokalemia. Front Pediatr. 2021;8:543309. doi: 10.3389/fped.2020.543309
57. Gartlehner G, Vander Schaaf EB, Orr C, et al. Screening for Hypertension in Children and Adolescents: Systematic Review for the U.S. Preventive Services Task Force [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2020 Nov. (Evidence Synthesis, No. 193.) Available online: https://www.ncbi.nlm.nih.gov/books/NBK564973. Accessed on October 7, 2021.
58. Erratum Flynn JT, Kaelber DC, Baker-Smith CM, et al. SUBCOMMITTEE ON SCREENING AND MANAGEMENT OF HIGH BLOOD PRESSURE IN CHILDREN. Clinical Practice Guideline for Screening and Management of High Blood Pressure in Children and Adolescents. Pediatrics. 2017;140(3):e20171904. Pediatrics. 2017;140(6):e20173035. doi: 10.1542/peds.2017-3035
59. Misurac J, Nichols KR, Wilson AC. Pharmacologic Management of Pediatric Hypertension. Paediatr Drugs. 2016;18(1):31-43. doi: 10.1007/s40272-015-0151-3
60. Sorof JM, Cargo P, Graepel J, et al. Beta-blocker/thiazide combination for treatment of hypertensive children: a randomised doubleblind, placebo-controlled trial. Pediatr Nephrol. 2002;17(5):345-350. doi: 10.1007/s00467-002-0851-0
61. Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358(15):1547-1559. doi: 10.1056/NEJMoa0801317
62. Parving HH, Brenner BM, McMurray JJ, et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med. 2012;367(23):2204-2213. doi: 10.1056/NEJMoa1208799
63. Fried LF, Emanuele N, Zhang JH, et al. Combined angio- tensin inhibition for the treatment of diabetic nephropathy. N Engl J Med. 2013;369(20):1892-1903. doi: 10.1056/NEJMoa1303154
64. Lubrano R, Soscia F, Elli M, et al. Renal and cardiovascular effects of angiotensin-converting enzyme inhibitor plus angiotensin II receptor antagonist therapy in children with proteinuria. Pediatrics. 2006;118:e833-e838. doi: 10.1542/peds.2005-2053
65. Snauwaert E, Vande Walle J, De Bruyne P Therapeutic efficacy and safety of ACE inhibitors in the hypertensive paediatric population: a review. Arch Dis Child. 2017;102(1):63-71. doi: 10.1136/archdischild-2016-310582
66. Schaefer F, van de Walle J, Zurowska A, et al. Candesartan in Children with Hypertension Investigators. Efficacy, safety and pharmacokinetics of candesartan cilexetil in hypertensive children from 1 to less than 6 years of age. J Hypertens. 2010;28:1083-1090. doi: 10.1097/HJH.0b013e328336b86b
67. Flynn JT, Meyers KE, Neto JP, et al. Efficacy and safety of the angiotensin receptor blocker valsartan in children with hypertension aged 1 to 5 years. Hypertension. 2008;52(2):222-228. doi: 10.1161/HYPERTENSIONAHA.108.111054
68. Siddiqi N, Shatat IF. Antihypertensive agents: a long way to safe drug prescribing in children. Pediatr Nephrol. 2020;35(11):2049-2065. doi: 10.1007/s00467-019-04314-7
69. Sahney S. A review of calcium channel antagonists in the treatment of pediatric hypertension. Paediatr Drugs. 2006;8(6):357-373. doi: 10.2165/00148581-200608060-00004
70. Poirier L, Lacourciere Y. The evolving role of p-adrenergic receptor blockers in managing hypertension. Can J Cardiol. 2012;28(3):334-340. doi: 10.1016/j.cjca.2012.04.001
71. Vachek J. The use of moxonidine in the treatment of arterial hypertension. Vnitr Lek. 2021;67(3):170-172.
72. Leontyeva IV, Balykova LA, Kudashova AV. Treatment of emergency conditions (hypertensive crisis) in children with arterial hypertension. Rossiyskiy Vestnik Perinatologii i Pediatrii = Russian Bulletin of Perinatology and Pediatrics. 2020;65:(3):147-152. (In Russ). doi: 10.21508/1027-4065-2020-65-3-147-152
Review
For citations:
Balykova L.A., Leontyeva I.V., Krasnopolskaya A.V., Sadykova D.I., Mashkina L.S., Chegodaeva I.Yu., Khabibrakhmanova Z.R., Slastnikova E.S., Galimova L.F., Ushakova S.A. Current Approaches to Arterial Hypertension Management in Children and Adolescents: Clinical Guidelines Review. Current Pediatrics. 2021;20(4):271-281. (In Russ.) https://doi.org/10.15690/vsp.v20i4.2281
Views:
3078
Email this article 
